This Article Full Text Full Text (PDF) All Versions of this Article: 23/6/1116    most recent 01.ATV.0000074146.36646.C8v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Post, M. S. Articles by Stehouwer, C. D.A. Search for Related Content PubMed PubMed Citation Articles by Post, M. S. Articles by Stehouwer, C. D.A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ESTRADIOL GESTODENE Related Collections Deep vein thrombosis Coagulation Thrombosis risk factors Other Treatment

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:1116.)
© 2003 American Heart Association, Inc.

Thrombosis

Effect of Oral and Transdermal Estrogen Replacement Therapy on Hemostatic Variables Associated With Venous Thrombosis

A Randomized, Placebo-Controlled Study in Postmenopausal Women

Marinka S. Post; M. Christella; L.G.D. Thomassen; Marius J. van der Mooren; W. Marchien van Baal; Jan Rosing; Peter Kenemans; Coen D.A. Stehouwer

From Project "Aging Women" and the Institute for Cardiovascular Research-Vrije Universiteit, Departments of Obstetrics & Gynecology (M.S.P., M.J.v.d.M., W.M.v.B., P.K.) and Internal Medicine (C.D.A.S.), VU University Medical Center, Amsterdam, and Department of Biochemistry, Cardiovascular Research Institute Maastricht (M.C.L.G.D.T., J.R.), Maastricht University, Maastricht, The Netherlands.

Correspondence to C.D.A. Stehouwer, Department of Internal Medicine, VU University Medical Center, De Boelelaan 1117, PO Box 7057,1007 MB Amsterdam, The Netherlands. E-mail cda.stehouwer{at}VUmc.nl

Objective— The purpose of this study was to investigate whether the effect of transdermal estrogen therapy in postmenopausal women differs from that of oral therapy with regard to resistance to activated protein C (APC), an important risk factor for venous thrombosis, and levels of related proteins, such as protein S, protein C, and prothrombin.

Methods and Results— In a randomized, double-blind, placebo-controlled study, 152 healthy hysterectomized postmenopausal women received daily either placebo (n=49), transdermal 17ß-estradiol (E₂) 50 µg (tE₂ group, n=33), oral E₂ 1 mg (oE₂ group, n=37), or oral E₂ 1 mg combined with gestodene 25 µg (oE₂+G group, n=33) for 13 28-day treatment cycles, followed by 4 cycles of placebo for each group. Plasma samples were collected at baseline and in cycles 4, 13, and 17. In cycle 13, significant increases versus baseline and placebo were found in normalized APC sensitivity ratios (nAPCsr) in all treated groups (tE₂, +26.9%; oE₂, +102.7%; oE₂+G, +69.9%). Increases in nAPCsr were significantly higher in the oral treatment groups than in the tE₂ group. In addition, compared with baseline and placebo, after 13 cycles, decreases were observed in total protein S (tE₂, -4.1%; oE₂, -7.9%; oE₂+G, -5.8%), free protein S (tE₂, -7.1%; oE₂, -8.4%; oE₂+G, -5.2%), and protein C in the oE₂+G group (-6.4%), but these changes did not explain the increase in nAPCsr. Changes in prothrombin were small and also did not affect the nAPCsr.

Conclusions— Increases were observed in resistance to APC, which were more pronounced in the oral treatment groups than in the transdermal group. The increase in resistance to APC was not explained by changes in protein S, protein C, or prothrombin and may contribute to the increased incidence of venous thrombosis in users of hormone replacement therapy.

Key Words: resistance to activated protein C • protein S • protein C • estrogen replacement therapy • venous thrombosis

This article has been cited by other articles:

				C. J. Glueck, Ping Wang, R. Hutchins, M. R. Petersen, and K. Golnik Ocular Vascular Thrombotic Events: Central Retinal Vein and Central Retinal Artery Occlusions Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 286 - 294. [Abstract] [PDF]

				M. Canonico, G. Plu-Bureau, G. D O Lowe, and P.-Y. Scarabin Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis BMJ, May 31, 2008; 336(7655): 1227 - 1231. [Abstract] [Full Text] [PDF]

				M. Canonico, E. Oger, G. Plu-Bureau, J. Conard, G. Meyer, H. Levesque, N. Trillot, M.-T. Barrellier, D. Wahl, J. Emmerich, et al. Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study Circulation, February 20, 2007; 115(7): 840 - 845. [Abstract] [Full Text] [PDF]

				N. L. Smith, S. R. Heckbert, R. N. Lemaitre, A. P. Reiner, T. Lumley, F. R. Rosendaal, and B. M. Psaty Conjugated Equine Estrogen, Esterified Estrogen, Prothrombotic Variants, and the Risk of Venous Thrombosis in Postmenopausal Women Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2807 - 2812. [Abstract] [Full Text] [PDF]

				J. L. Turgeon, M. C. Carr, P. M. Maki, M. E. Mendelsohn, and P. M. Wise Complex Actions of Sex Steroids in Adipose Tissue, the Cardiovascular System, and Brain: Insights from Basic Science and Clinical Studies Endocr. Rev., October 1, 2006; 27(6): 575 - 605. [Abstract] [Full Text] [PDF]

				D. F. Gunther and D. S. Diekema Attenuating growth in children with profound developmental disability: a new approach to an old dilemma. Arch Pediatr Adolesc Med, October 1, 2006; 160(10): 1013 - 1017. [Abstract] [Full Text] [PDF]

				M. Hemelaar, J. Rosing, P. Kenemans, M. C. L.G.D. Thomassen, D. D.M. Braat, and M. J. van der Mooren Less Effect of Intranasal Than Oral Hormone Therapy on Factors Associated With Venous Thrombosis Risk in Healthy Postmenopausal Women Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1660 - 1666. [Abstract] [Full Text] [PDF]

				C. Straczek, E. Oger, M. B. Yon de Jonage-Canonico, G. Plu-Bureau, J. Conard, G. Meyer, M. Alhenc-Gelas, H. Levesque, N. Trillot, M.-T. Barrellier, et al. Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration Circulation, November 29, 2005; 112(22): 3495 - 3500. [Abstract] [Full Text] [PDF]

				C. E. GLEASON, C. M. CARLSSON, S. JOHNSON, C. ATWOOD, and S. ASTHANA Clinical Pharmacology and Differential Cognitive Efficacy of Estrogen Preparations Ann. N.Y. Acad. Sci., June 1, 2005; 1052(1): 93 - 115. [Abstract] [Full Text] [PDF]

				R. G. V. Smolders, K. de Meer, P. Kenemans, C. Jakobs, W. Kulik, and M. J. van der Mooren Oral Estradiol Decreases Plasma Homocysteine, Vitamin B6, and Albumin in Postmenopausal Women But Does Not Change the Whole-Body Homocysteine Remethylation and Transmethylation Flux J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2218 - 2224. [Abstract] [Full Text] [PDF]

				C. J. Glueck, N. Goldenberg, P. Wang, and D. Aregawi Ramifications of Four Concurrent Thrombophilic Mutations and One Hypofibrinolytic Mutation Clinical and Applied Thrombosis/Hemostasis, October 1, 2004; 10(4): 365 - 371. [Abstract] [PDF]